Psoriatic arthritis is an inflammatory arthritis that significantly impairs patient quality of life and affects multiple domains of life. Lifestyle modification has the potential to improve disease activity and quality of life. We review the cellular pathophysiology of psoriatic arthritis to better understand why lifestyle interventions can make a positive impact on disease, and we discuss the interventions that can be made to treat psoriatic arthritis, including weight loss and dietary changes, exercise, improvements in sleep, alcohol moderation, smoking cessation, and psychologic interventions.
McGonagleDGibbonWEmeryP. Classification of inflammatory arthritis by enthesitis. Lancet. 1998;352(9134):1137-1140. doi:10.1016/S0140-6736(97)12004-9
3.
TaylorWGladmanDHelliwellPMarchesoniAMeasePMielantsHCASPAR Study Group. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-2673. doi:10.1002/art.21972. https://onlinelibrary.wiley.com/doi/abs/10.1002/art.21972
4.
CharltonRGreenAShaddickG, et al.Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: A population-based cohort study. Ann Rheum Dis. 2018;77(2):277-280. doi:10.1136/annrheumdis-2017-212328
5.
NiccoliLNanniniCCassaràE, et al.Frequency of iridocyclitis in patients with early psoriatic arthritis: A prospective, follow up study. Int J Rheum Dis. 2012;15(4):414-418. doi:10.1111/j.1756-185X.2012.01736.x. https://api.istex.fr/ark:/67375/WNG-4FSM3GSF-7/fulltext.pdf
6.
GelfandJMGladmanDDMeasePJ, et al.Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573-573.e13. doi:10.1016/j.jaad.2005.03.046
EderLHaddadARosenCF, et al.The incidence and risk factors for psoriatic arthritis in patients with psoriasis: A prospective cohort study. Arthritis Rheumatol. 2016;68(4):915-923. doi:10.1002/art.39494. https://onlinelibrary.wiley.com/doi/abs/10.1002/art.39494
10.
Soltani-ArabshahiRWongBFengBGoldgarDEDuffinKCKruegerGG. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol (1960). 2010;146(7):721-726. doi:10.1001/archdermatol.2010.141
11.
LangenbruchARadtkeMAKrenselMJacobiAReichKAugustinM. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol (1951). 2014;171(5):1123-1128. doi:10.1111/bjd.13272. https://api.istex.fr/ark:/67375/WNG-BS3J0LFL-J/fulltext.pdf
12.
WilsonFCIcenMCrowsonCSMcEvoyMTGabrielSEKremersHM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study. Arthritis Rheum. 2009;61(2):233-239. doi:10.1002/art.24172. https://onlinelibrary.wiley.com/doi/abs/10.1002/art.24172
13.
EderLLawTChandranV, et al.Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res (2010). 2011;63(8):1091-1097. doi:10.1002/acr.20496. https://onlinelibrary.wiley.com/doi/abs/10.1002/acr.20496
14.
LoveTJZhuYZhangY, et al.Obesity and the risk of psoriatic arthritis: A population-based study. Ann Rheum Dis. 2012;71(8):1273-1277. doi:10.1136/annrheumdis-2012-201299
15.
ZabottiADe LuciaOSakellariouG, et al.Predictors, risk factors, and incidence rates of psoriatic arthritis development in psoriasis patients: A systematic literature review and meta-analysis. Rheumatol Ther. 2021;8(4):1519-1534. doi:10.1007/s40744-021-00378-w. https://link.springer.com/article/10.1007/s40744-021-00378-w
16.
LiWHanJQureshiAA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012;71(8):1267-1272. doi:10.1136/annrheumdis-2011-201273
17.
ThomsenRSNilsenTILHaugebergGGulatiAMKavanaughAHoffM. Adiposity and physical activity as risk factors for developing psoriatic arthritis: Longitudinal data from a population-based study in Norway. Arthritis Care Res. 2021;73(3):432-441. doi:10.1002/acr.24121
18.
LoganathanAKamalarajNEl-haddadCPileK. Systematic review and meta-analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis. Int J Rheum Dis. 2021;24(9):1112-1120. doi:10.1111/1756-185x.14147
19.
ChandranVSchentagCTBrockbankJE, et al.Familial aggregation of psoriatic arthritis. Ann Rheum Dis. 2009;68(5):664-667. doi:10.1136/ard.2008.089367
20.
KarasonALoveTJGudbjornssonB. A strong heritability of psoriatic arthritis over four generations—the Reykjavik psoriatic arthritis study. Rheumatology. 2009;48(11):1424-1428. doi:10.1093/rheumatology/kep243. https://api.istex.fr/ark:/67375/HXZ-5LRR3NN9-K/fulltext.pdf
TinazziIMcGonagleDAydinSZChessaDMarchettaAMacchioniP. ‘Deep koebner’ phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis. Ann Rheum Dis. 2018;77(6):922-925. doi:10.1136/annrheumdis-2017-212681
Cuervo AguileraAFuentelsaz-RomeroSEstrada-CapetilloL, et al.AB0087 Synovial tissue macrophages polarisation (M1, M2) in patients with undifferentiated arthritis meeting diagnostic criteria for rheumatoid arthritis or psoriatic arthritis along the follow up. Ann Rheum Dis. 2018;77(Suppl 2):1240.
25.
MollCBogasMGómez-PuertaJA, et al.Macroscopic features of knee synovitis in early untreated behçet disease and psoriatic arthritis. Clin Rheumatol. 2009;28(9):1053-1057. doi:10.1007/s10067-009-1205-0. https://link.springer.com/article/10.1007/s10067-009-1205-0
26.
Van KuijkAWRReinders-BlankertPSmeetsTJMDijkmansBACTakPP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: Implications for treatment. Ann Rheum Dis. 2006;65(12):1551-1557. doi:10.1136/ard.2005.050963
27.
VealeDJFearonU. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273-2284. doi:10.1016/S0140-6736(18)30830-4
SoareAWeberSMaulL, et al.Cutting edge: Homeostasis of innate lymphoid cells is imbalanced in psoriatic arthritis. J Immunol. 2018;200(4):1249-1254. doi:10.4049/jimmunol.1700596
31.
CandiaLMarquezJHernandezCZeaAHEspinozaLR. Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: A pathogenic role for innate immunity?J Rheumatol. 2007;34(2):374-379. http://www.jrheum.org/content/34/2/374.abstract
32.
SinghRKoppuSPerchePOFeldmanSR. The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications. Int J Mol Sci. 2021;22(23):12793. doi:10.3390/ijms222312793
33.
RaychaudhuriSPRaychaudhuriSKGenoveseMC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359(1-2):419-429. doi:10.1007/s11010-011-1036-6. https://link.springer.com/article/10.1007/s11010-011-1036-6
34.
MitraARaychaudhuriSKRaychaudhuriSP. Functional role of IL-22 in psoriatic arthritis. Arthritis Res Ther. 2012;14(2):R65. doi:10.1186/ar3781. https://www.ncbi.nlm.nih.gov/pubmed/22417743
35.
YagoTNankeYKawamotoM, et al.IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther. 2007;9(5):R96. doi:10.1186/ar2297. https://www.ncbi.nlm.nih.gov/pubmed/17888176
36.
AggarwalSGhilardiNXieMde SauvageFJGurneyAL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278(3):1910-1914. doi:10.1074/jbc.M207577200
37.
KimKKimHParkJ, et al.Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum. 2012;64(4):1015-1023. doi:10.1002/art.33446. https://api.istex.fr/ark:/67375/WNG-GPQ1XPS5-S/fulltext.pdf
38.
MiyazakiYNakayamadaSKuboS, et al.Th22 cells promote osteoclast differentiation via production of IL-22 in rheumatoid arthritis. Front Immunol. 2018;9:2901. doi:10.3389/fimmu.2018.02901
PaccouJBavièreWSornay-RenduE, et al.Body composition in patients with psoriatic arthritis and changes during interleukin 12/23 inhibition. Arthritis Care Res. 2012:74:1608. doi:10.1002/acr.24623. https://www.ncbi.nlm.nih.gov/pubmed/33973385
41.
MenonBGullickNJWalterGJ, et al.Interleukin-17+ CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014;66(5):1272-1281. doi:10.1002/art.38376. https://onlinelibrary.wiley.com/doi/abs/10.1002/art.38376
42.
AraujoEGEnglbrechtMHoepkenS, et al.Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2019;48(4):632-637. doi:10.1016/j.semarthrit.2018.05.011
43.
MeasePJMcInnesIBKirkhamB, et al.Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329-1339. doi:10.1056/NEJMoa1412679. https://nejm.org/doi/full/10.1056/NEJMoa1412679
44.
MeasePvan der HeijdeDLandewéR, et al.Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: Primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890-897. doi:10.1136/annrheumdis-2017-212687
45.
KavanaughARitchlinCRahmanP, et al.Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73(6):1000-1006. doi:10.1136/annrheumdis-2013-204741
46.
RitchlinCRahmanPKavanaughA, et al.Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990-999. doi:10.1136/annrheumdis-2013-204655
47.
NashPKirkhamBOkadaM, et al.Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: Results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet (London, England). 2017;389(10086):2317-2327. doi:10.1016/S0140-6736(17)31429-0. https://www.clinicalkey.es/playcontent/1-s2.0-S0140673617314290
48.
DeodharAGottliebABBoehnckeW, et al.Efficacy and safety of guselkumab in patients with active psoriatic arthritis: A randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018;391(10136):2213-2224. doi:10.1016/S0140-6736(18)30952-8
49.
ReillySMSaltielAR. Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol. 2017;13(11):633-643. doi:10.1038/nrendo.2017.90. https://www.ncbi.nlm.nih.gov/pubmed/28799554
50.
NishimuraSManabeINagasakiM, et al.CD8 + effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009;15(8):914-920. doi:10.1038/nm.1964
HotamisligilGSShargillNSSpiegelmanBM. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87-91. doi:10.1126/science.7678183. http://www.sciencemag.org/cgi/content/abstract/259/5091/87
53.
KawanishiNNiiharaHMizokamiTYadaKSuzukiK. Exercise training attenuates neutrophil infiltration and elastase expression in adipose tissue of high-fat-diet-induced obese mice. Phys Rep. 2015;3(9):e12534. doi:10.14814/phy2.12534
54.
Zahorska-MarkiewiczBJanowskaJOlszanecka-GlinianowiczMZurakowskiA. Serum concentrations of TNF-alpha and soluble TNF-alpha receptors in obesity. Int J Obes Relat Metab Disord. 2000;24(11):1392-1395. doi:10.1038/sj.ijo.0801398. https://www.ncbi.nlm.nih.gov/pubmed/11126333
RodaJMEubankTD. The Cellular Component of Chronic Inflammation. Boca Raton, FL: CRC Press; 2012. doi:10.1201/b12696-4
57.
BertolaACiucciTRousseauD, et al.Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. Diabetes. 2012;61(9):2238-2247. doi:10.2337/db11-1274. https://www.ncbi.nlm.nih.gov/pubmed/22596049
58.
WinerSChanYPaltserG, et al.Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med. 2009;15(8):921-929. doi:10.1038/nm.2001
59.
StrisselKJDeFuriaJShaulMEBennettGGreenbergASObinMS. T-cell recruitment and Th1 polarization in adipose tissue during diet-induced obesity in C57BL/6 mice. Obesity. 2010;18(10):1918-1925. doi:10.1038/oby.2010.1
ZhaoRTangDYiS, et al.Elevated peripheral frequencies of Th22 cells: A novel potent participant in obesity and type 2 diabetes. PLoS One. 2014;9(1):e85770. doi:10.1371/journal.pone.0085770. https://www.ncbi.nlm.nih.gov/pubmed/24465695
63.
DalmasEVenteclefNCaerC, et al.T cell–derived IL-22 amplifies IL-1β–driven inflammation in human adipose tissue: Relevance to obesity and type 2 diabetes. Diabetes. 2014;63(6):1966-1977. doi:10.2337/db13-1511. https://www.ncbi.nlm.nih.gov/pubmed/24520123
64.
FabbriniECellaMMccartneySA, et al.Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterology (New York, NY, 1943). 2013;145(2):366-374. doi:10.1053/j.gastro.2013.04.010. https://www.clinicalkey.es/playcontent/1-s2.0-S0016508513005118
65.
Sumarac-DumanovicMStevanovicDLjubicA, et al.Increased activity of interleukin-23 interleukin-17 proinflammatory axis in obese women. Int J Obes. 2009;33(1):151-156. doi:10.1038/ijo.2008.216
66.
Sumarac-DumanovicMJeremicDPantovicA, et al.Therapeutic improvement of glucoregulation in newly diagnosed type 2 diabetes patients is associated with a reduction of IL-17 levels. Immunobiology (1979). 2013;218(8):1113-1118. doi:10.1016/j.imbio.2013.03.002. https://www.clinicalkey.es/playcontent/1-s2.0-S0171298513000429
67.
ZúñigaLAShenWJoyce-ShaikhB, et al.IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol (1950). 2010;185(11):6947-6959. doi: 10.4049/jimmunol.1001269. https://www.ncbi.nlm.nih.gov/pubmed/21037091
RibeiroSMTLLopesLRPaula CostaG, et al.CXCL-16, IL-17, and bone morphogenetic protein 2 (BMP-2) are associated with overweight and obesity conditions in middle-aged and elderly women. Immun Ageing. 2017;14(1):6. doi:10.1186/s12979-017-0089-0
70.
BholeVMChoiHKBurnsLC, et al.Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology. 2012;51(3):552-556. doi:10.1093/rheumatology/ker349. https://www.ncbi.nlm.nih.gov/pubmed/22120603
71.
GreenAShaddickGCharltonR, et al.Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. Br J Dermatol. 2020;182(3):714-720. doi:10.1111/bjd.18227
FeldJNissanSEderL, et al.Increased prevalence of metabolic syndrome and adipocytokine levels in a psoriatic arthritis cohort. J Clin Rheumatol. 2018;24(6):302-307. doi:10.1097/RHU.0000000000000721. https://www.ncbi.nlm.nih.gov/pubmed/29708516
74.
KlingbergEBilbergABjörkmanS, et al.Weight loss improves disease activity in patients with psoriatic arthritis and obesity: An interventional study. Arthritis Res Ther. 2019;21(1):17. doi:10.1186/s13075-019-1810-5
75.
GokKNasKTekeogluI, et al.Impact of obesity on quality of life, psychological status, and disease activity in psoriatic arthritis: A multi-center study. Rheumatol Int. 2022;42(4):659-668. doi:10.1007/s00296-021-04971-8. https://link.springer.com/article/10.1007/s00296-021-04971-8
76.
di MinnoMNDPelusoRIervolinoS, et al.Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis. Arthritis Care Res (2010). 2013;65(1):141-147. doi: 10.1002/acr.21711. https://onlinelibrary.wiley.com/doi/abs/10.1002/acr.21711
77.
HøjgaardPGlintborgBKristensenLEGudbjornssonBLoveTJDreyerL. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: Results from the DANBIO and ICEBIO registries. Rheumatology. 2016;55(12):2191-2199. doi:10.1093/rheumatology/kew326
78.
EderLThavaneswaranAChandranVCookRJGladmanDD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015;74(5):813-817. doi:10.1136/annrheumdis-2013-204448
79.
DaviesMJBergenstalRBodeB, et al.Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. JAMA, J Am Med Assoc. 2015;314(7):687-699. doi:10.1001/jama.2015.9676
80.
O'NeilPMBirkenfeldALMcGowanB, et al.Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637-649. doi:10.1016/S0140-6736(18)31773-2
81.
JastreboffAMAronneLJAhmadNN, et al.Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. https://nejm.org/doi/full/10.1056/NEJMoa2206038
82.
ReidCTTobinAMAhernTO’SheaDKirbyB. Liraglutide in combination with acitretin for severe recalcitrant psoriasis. Br J Dermatol (1951). 2013;169(1):230-231. doi:10.1111/bjd.12380. https://api.istex.fr/ark:/67375/WNG-7WWR9WZX-N/fulltext.pdf
83.
CostanzoGCuratoloSBusàBBelfioreAGulloD. Two birds one stone: Semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep. 2021;2021(1):1-4. doi:10.1530/EDM-21-0007
84.
FaurschouAGyldenløveMRohdeU, et al.Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients - a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015;29(3):555-559. doi:10.1111/jdv.12629. https://api.istex.fr/ark:/67375/WNG-V56TK452-0/fulltext.pdf
85.
HoganAETobinAMAhernT, et al.Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: Lessons from obesity, diabetes and psoriasis. Diabetologia. 2011;54(11):2745-2754. doi:10.1007/s00125-011-2232-3. https://link.springer.com/article/10.1007/s00125-011-2232-3
86.
LeiteBFMorimotoMAGomesCMF, et al.Dietetic intervention in psoriatic arthritis: The DIETA trial. Adv Rheumatol. 2022;62(1):12. doi:10.1186/s42358-022-00243-6. https://www.ncbi.nlm.nih.gov/pubmed/35387686
87.
KlingbergEBjörkmanSEliassonBLarssonIBilbergA. Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: A prospective intervention study with two years of follow-up. Arthritis Res Ther. 2020;22(1):254-254. doi:10.1186/s13075-020-02350-5. https://search.proquest.com/docview/2461850068
88.
Di MinnoMNDPelusoRIervolinoSRussolilloALupoliRScarpaRCaRRDs Study Group. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2014;73(6):1157-1162. doi:10.1136/annrheumdis-2012-202812
89.
ShivappaNSteckSEHurleyTGHusseyJRHebertJR. Designing and developing a literature-derived, population-based dietary inflammatory index. Publ Health Nutr. 2014;17(8):1689-1696. doi:10.1017/S1368980013002115. https://www.ncbi.nlm.nih.gov/pubmed/23941862
90.
NorthCJVenterCSJerlingJC. The effects of dietary fibre on C-reactive protein, an inflammation marker predicting cardiovascular disease. Eur J Clin Nutr. 2009;63(8):921-933. doi:10.1038/ejcn.2009.8
91.
AkbaralyTNShipleyMJFerrieJE, et al.Long-term adherence to healthy dietary guidelines and chronic inflammation in the prospective whitehall II study. Am J Med. 2015;128(2):152-160. doi:10.1016/j.amjmed.2014.10.002. https://www.clinicalkey.es/playcontent/1-s2.0-S0002934314008572
WenHGrisDLeiY, et al.Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011;12(5):408-415. doi:10.1038/ni.2022. https://www.ncbi.nlm.nih.gov/pubmed/21478880
94.
KingDEEganBMGeeseyME. Relation of dietary fat and fiber to elevation of C-reactive protein. Am J Cardiol. 2003;92(11):1335-1339. doi:10.1016/j.amjcard.2003.08.020
95.
BjermoHIggmanDKullbergJ, et al.Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: A randomized controlled trial. Am J Clin Nutr. 2012;95(5):1003-1012. doi:10.3945/ajcn.111.030114. https://www.ncbi.nlm.nih.gov/pubmed/22492369
96.
DwyerJHAllayeeHDwyerKM, et al.Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. J Vasc Surg. 2004;39(6):1357. doi:10.1016/j.jvs.2004.03.014
97.
NooriNDukkipatiRKovesdyCP, et al.Dietary omega-3 fatty acid, ratio of omega-6 to omega-3 intake, inflammation, and survival in long-term hemodialysis patients. Am J Kidney Dis. 2011;58(2):248-256. doi:10.1053/j.ajkd.2011.03.017. https://www.clinicalkey.es/playcontent/1-s2.0-S0272638611007232
98.
SofiFAbbateRGensiniGFCasiniA. Accruing evidence on benefits of adherence to the mediterranean diet on health: An updated systematic review and meta-analysis. Am J Clin Nutr. 2010;92(5):1189-1196. doi:10.3945/ajcn.2010.29673. https://www.ncbi.nlm.nih.gov/pubmed/20810976
Quetglas-LlabrésMMMonserrat-MesquidaMBouzasC, et al.Inflammatory and oxidative stress markers related to adherence to the mediterranean diet in patients with metabolic syndrome. Antioxidants. 2022;11(5):901. doi:10.3390/antiox11050901
101.
ChrysohoouCPanagiotakosDBPitsavosCDasUNStefanadisC. Adherence to the mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA study. J Am Coll Cardiol. 2004;44(1):152-158. doi:10.1016/j.jacc.2004.03.039
102.
EspositoKMarfellaRCiotolaM, et al.Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome. A randomized trial. ACC Curr J Rev. 2004;13(12):16-17. doi:10.1016/j.accreview.2004.11.073
103.
ObarzanekESacksFMVollmerWM, et al.Effects on blood lipids of a blood pressure-lowering diet: The dietary approaches to stop hypertension (DASH) trial. Am J Clin Nutr. 2001;74(1):80-89. doi:10.1093/ajcn/74.1.80. https://www.ncbi.nlm.nih.gov/pubmed/11451721
104.
ShinPParkSKimMS, et al.A traditional Korean diet with a low dietary inflammatory index increases anti-inflammatory IL-10 and decreases pro-inflammatory NF-κB in a small dietary intervention study. Nutrients. 2020;12(8):2468. doi:10.3390/nu12082468
105.
SoltaniSChitsaziMJSalehi-AbargoueiA. The effect of dietary approaches to stop hypertension (DASH) on serum inflammatory markers: A systematic review and meta-analysis of randomized trials. Clin Nutr. 2018;37(2):542-550. doi:10.1016/j.clnu.2017.02.018. https://www.clinicalkey.es/playcontent/1-s2.0-S0261561417300687
106.
SakhaeiRShahvaziSMozaffari-KhosraviH, et al.The dietary approaches to stop hypertension (DASH)-style diet and an alternative mediterranean diet are differently associated with serum inflammatory markers in female adults. Food Nutr Bull. 2018;39(3):361-376. doi:10.1177/0379572118783950. https://journals.sagepub.com/doi/full/10.1177/0379572118783950
107.
BoloriPSetayshLRasaeiNJarrahiFYekaninejadMSMirzaeik. Adherence to a healthy plant diet may reduce inflammatory factors in obese and overweight women-a cross-sectional study. Diabetes Metabol Syndr. 2019;13(4):2795-2802. doi:10.1016/j.dsx.2019.07.019
108.
MenzelJJabakhanjiABiemannRMaiKAbrahamKWeikertC. Systematic review and meta-analysis of the associations of vegan and vegetarian diets with inflammatory biomarkers. Sci Rep. 2020;10(1):21736. doi:10.1038/s41598-020-78426-8
109.
CraddockJCNealeEPPeoplesGEProbstYC. Vegetarian-based dietary patterns and their relation with inflammatory and immune biomarkers: A systematic review and meta-analysis. Adv Nutr. 2019;10(3):433-451. doi:10.1093/advances/nmy103. https://www.ncbi.nlm.nih.gov/pubmed/30947338
110.
KashaniAMoludiJLateef FatehHTandorostAJafari-VayghanHDeyP. Dietary inflammatory index in relation to psoriasis risk, cardiovascular risk factors, and clinical outcomes: A case-control study in psoriasis patients. Appl Physiol Nutr Metabol. 2021;46(12):1517-1524. doi:10.1139/apnm-2021-0217. https://www.ncbi.nlm.nih.gov/pubmed/34348057
111.
BarreaLBalatoNDi SommaC, et al.Nutrition and psoriasis: Is there any association between the severity of the disease and adherence to the mediterranean diet?J Transl Med. 2015;13(1):18. doi:10.1186/s12967-014-0372-1. https://www.ncbi.nlm.nih.gov/pubmed/25622660
112.
BarreaLMacchiaPETarantinoG, et al.Nutrition: A key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire. J Transl Med. 2015;13(1):303. doi:10.1186/s12967-015-0658-y
113.
PhanCTouvierMKesse-GuyotE, et al.Association between mediterranean anti-inflammatory dietary profile and severity of psoriasis: Results from the nutriNet-santé cohort. JAMA Dermatol. 2018;154(9):1017-1024. doi:10.1001/jamadermatol.2018.2127
114.
CasoFNavariniLCarubbiF, et al.Mediterranean diet and psoriatic arthritis activity: A multicenter cross-sectional study. Rheumatol Int. 2020;40(6):951-958. doi:10.1007/s00296-019-04458-7. https://link.springer.com/article/10.1007/s00296-019-04458-7
115.
FordARSiegelMBagelJ, et al.Dietary recommendations for adults with psoriasis or psoriatic arthritis from the medical board of the national psoriasis foundation: A systematic review. JAMA Dermatol. 2018;154(8):934-950. doi:10.1001/jamadermatol.2018.1412
IngkapairojKChularojanamontriLChaiyabutrCSilpa-archaNWongpraparutCBunyaratavejS. Dietary habits and perceptions of psoriatic patients: Mediterranean versus Asian diets. J Dermatol Treat. 2022;33(4):2290-2296. doi:10.1080/09546634.2021.1959500. https://www.tandfonline.com/doi/abs/10.1080/09546634.2021.1959500
118.
OvergaardSHSørensenSBMunkHL, et al.Impact of fibre and red/processed meat intake on treatment outcomes among patients with chronic inflammatory diseases initiating biological therapy: A prospective cohort study. Front Nutr. 2022;9:985732. doi:10.3389/fnut.2022.985732. https://www.ncbi.nlm.nih.gov/pubmed/36313095
119.
Abou-RayaAAbou-RayaSHelmiiM. OP0076 Effect of exercise and dietary weight loss on symptoms and systemic inflammation in obese adults with psoriatic arthritis: Randomized controlled trial. Ann Rheum Dis. 2014;73(Suppl 2):89-90. doi:10.1136/annrheumdis-2014-eular.2760
120.
Roger-SilvaDNatourJMoreiraEJenningsF. A resistance exercise program improves functional capacity of patients with psoriatic arthritis: A randomized controlled trial. Clin Rheumatol. 2018;37(2):389-395. doi:10.1007/s10067-017-3917-x. https://link.springer.com/article/10.1007/s10067-017-3917-x
121.
BalducciSZanusoSNicolucciA, et al.Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss. Nutr Metabol Cardiovasc Dis. 2010;20(8):608-617. doi:10.1016/j.numecd.2009.04.015. https://www.clinicalkey.es/playcontent/1-s2.0-S0939475309001070
122.
HoSSDhaliwalSSHillsAPPalS. Effects of chronic exercise training on inflammatory markers in Australian overweight and obese individuals in a randomized controlled trial. Inflammation. 2013;36(3):625-632. doi:10.1007/s10753-012-9584-9. https://link.springer.com/article/10.1007/s10753-012-9584-9
123.
DiasIFarinattiPDe SouzaMGC, et al.Effects of resistance training on obese adolescents. Med Sci Sports Exerc. 2015;47(12):2636-2644. doi:10.1249/MSS.0000000000000705. https://www.ncbi.nlm.nih.gov/pubmed/25973557
124.
ThorarensenSMLuNOgdieAGelfandJMChoiHKLoveTJ. Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. Ann Rheum Dis. 2017;76(3):521-525. doi:10.1136/annrheumdis-2016-209334
ZhouWChandranVCookRGladmanDDEderL. The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis. Semin Arthritis Rheum. 2019;48(4):638-643. doi:10.1016/j.semarthrit.2018.06.001
127.
WerversKHerringsILuimeJJ, et al.Association of physical activity and medication with enthesitis on ultrasound in psoriatic arthritis. J Rheumatol. 2019;46(10):1290-1294. doi:10.3899/jrheum.180782. https://www.ncbi.nlm.nih.gov/pubmed/30824661
128.
SinghJAGuyattGOgdieA, et al.Special article: 2018 American college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol2019;71(1):5-32. doi:10.1002/art.40726. https://onlinelibrary.wiley.com/doi/abs/10.1002/art.40726
129.
BawaFLMMercerSWAthertonRJ, et al.Does mindfulness improve outcomes in patients with chronic pain? Systematic review and meta-analysis. Br J Gen Pract. 2015;65(635):e387-e400. doi:10.3399/bjgp15X685297. https://www.ncbi.nlm.nih.gov/pubmed/26009534
130.
MehdizadehAAliakbari DehkordiMNilforoushzadehMAAlipourAMansouriP. The comparison of the effectiveness of emotion - focused cognitive - behavioral therapy and mindfulness - based cognitive therapy on the socio - physical anxiety, itching, and psoriasis severity. The Journal of Psychological Science. 2020;19(87):349-359. doi:10.29252/psychosci.19.87.349. https://doaj.org/article/658a7e767eec49d39e92cb1b62f9acb3
Kabat-ZinnJWheelerELightT, et al.Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom Med. 1998;60(5):625-632. doi:10.1097/00006842-199809000-00020. https://www.ncbi.nlm.nih.gov/pubmed/9773769
133.
PiasericoSMarinelloEDessiALinderMDCoccarielliDPesericoA. Efficacy of biofeedback and cognitive-behavioural therapy in psoriatic PatientsA single-blind, randomized and controlled study with added narrow-band ultraviolet B therapy. Acta Derm Venereol. 2016;96(217):91-95. doi:10.2340/00015555-2428. https://www.ncbi.nlm.nih.gov/pubmed/27283367
van BeugenSFerwerdaMSpillekom-van KoulilS, et al.Tailored therapist-guided internet-based cognitive behavioral treatment for psoriasis: A randomized controlled trial. Psychother Psychosom. 2016;85(5):297-307. doi:10.1159/000447267. https://www.jstor.org/stable/48516016
136.
CarpenterJKAndrewsLAWitcraftSMPowersMBSmitsJAJHofmannSG. Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. Depress Anxiety. 2018;35(6):502-514. doi:10.1002/da.22728
137.
GossecLWalshJAMichaudK, et al.AB0821 anxiety and depression in Psoriatic Arthritis (PsA) - prevalence and impact on patient reported outcomes: Real-world survey in the US and Europe. Ann Rheum Dis. 2020;79(Suppl 1):1714. doi:10.1136/annrheumdis-2020-eular.5953
138.
Krajewska-WłodarczykMOwczarczyk-SaczonekAPlacekW. Sleep disorders in patients with psoriatic arthritis and psoriasis. Reumatologia. 2018;56(5):301-306. doi:10.5114/reum.2018.79501. https://www.ncbi.nlm.nih.gov/pubmed/30505012
139.
SkougaardMStisenZRJørgensenTS, et al.Increased prevalence of sleep disturbance in psoriatic arthritis is associated with inflammatory and non-inflammatory measures. Scand J Rheumatol. 2023;52(3):259-267. doi:10.1080/03009742.2022.2044116
140.
PalominosPECoatesLKohemCL, et al.Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. Joint Bone Spine. 2020;87(5):449-454. doi:10.1016/j.jbspin.2020.03.014
141.
WongITYChandranVLiSGladmanDD. Sleep disturbance in psoriatic disease: Prevalence and associated factors. J Rheumatol. 2017;44(9):1369-1374. doi:10.3899/jrheum.161330. https://www.ncbi.nlm.nih.gov/pubmed/28620064
142.
SmithMPLyKThibodeauxQ, et al.Factors influencing sleep difficulty and sleep quantity in the citizen pscientist psoriatic cohort. Dermatol Ther. 2019;9(3):511-523. doi:10.1007/s13555-019-0306-1. https://link.springer.com/article/10.1007/s13555-019-0306-1
143.
WongBMachanMKruegerGGDuffinKC. Increased prevalence of sleep disorders and medical comorbidities in psoriatic arthritis patients compared with patients with and without psoriasis. Psoriasis Forum. 2011;17a(3):209-215. doi:10.1177/247553031117a00305
144.
GezerOBatmazİSariyildizMA, et al.Sleep quality in patients with psoriatic arthritis. Int J Rheum Dis. 2017;20(9):1212-1218. doi:10.1111/1756-185x.12505
145.
HaugebergGHoffMKavanaughAMichelsenB. Psoriatic arthritis: Exploring the occurrence of sleep disturbances, fatigue, and depression and their correlates. Arthritis Res Ther. 2020;22(1):198-198. doi:10.1186/s13075-020-02294-w. https://search.proquest.com/docview/2444043804
146.
HuangYGuilleminaultCHwangF, et al.Inflammatory cytokines in pediatric obstructive sleep apnea. Medicine. 2016;95(41):e4944. doi:10.1097/MD.0000000000004944. https://www.ncbi.nlm.nih.gov/pubmed/27741107
147.
van LeeuwenWMALehtoMKarisolaP, et al.Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP. PLoS One. 2009;4(2):e4589. doi:10.1371/journal.pone.0004589. https://www.ncbi.nlm.nih.gov/pubmed/19240794
148.
PapadavidEDalamagaMVlamiK, et al.Psoriasis is associated with risk of obstructive sleep apnea independently from metabolic parameters and other comorbidities: A large hospital-based case-control study. Sleep Breath. 2017;21(4):949-958. doi:10.1007/s11325-017-1507-4. https://link.springer.com/article/10.1007/s11325-017-1507-4
149.
PapatriantafyllouEEfthymiouDZoumbaneasEPopescuCAVassilopoulouE. Sleep deprivation: Effects on weight loss and weight loss maintenance. Nutrients. 2022;14(8):1549. doi:10.3390/nu14081549. https://www.ncbi.nlm.nih.gov/pubmed/35458110
150.
ChungKLeeCYeungWChanMChungEWLinW. Sleep hygiene education as a treatment of insomnia: A systematic review and meta-analysis. Fam Pract. 2018;35(4):365-375. doi:10.1093/fampra/cmx122. https://www.ncbi.nlm.nih.gov/pubmed/29194467
151.
TrauerJMQianMYDoyleJSRajaratnamSMWCunningtonD. Cognitive behavioral therapy for chronic insomnia: A systematic review and meta-analysis. Ann Intern Med. 2015;163(3):191-204. doi:10.7326/M14-2841. https://www.ncbi.nlm.nih.gov/pubmed/26054060
152.
RicherVRoubilleCFlemingP, et al.Psoriasis and smoking: A systematic literature review and meta-analysis with qualitative analysis of effect of smoking on psoriasis severity. J Cutan Med Surg. 2016;20(3):221-227. doi:10.1177/1203475415616073. https://journals.sagepub.com/doi/full/10.1177/1203475415616073
153.
GerdesSZahlVAWeichenthalMMrowietzU. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology (Basel). 2010;220(1):38-43. doi:10.1159/000265557. https://www.karger.com/Article/Abstract/265557
154.
LiWHanJQureshiAA. Smoking and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012;71(6):804-808. doi:10.1136/annrheumdis-2011-200416
155.
NguyenUSDTZhangYLuN, et al.Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: A population-based study. Ann Rheum Dis. 2018;77(1):119-123. doi:10.1136/annrheumdis-2017-211625
156.
HøjgaardPGlintborgBHetlandML, et al.Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: Results from the DANBIO registry. Ann Rheum Dis. 2015;74(12):2130-2136. doi:10.1136/annrheumdis-2014-205389
157.
BremanderAJacobssonLTHBergmanSHaglundELöfvendahlSPeterssonIF. Smoking is associated with a worse self-reported health status in patients with psoriatic arthritis: Data from a Swedish population-based cohort. Clin Rheumatol. 2015;34(3):579-583. doi:10.1007/s10067-014-2742-8. https://link.springer.com/article/10.1007/s10067-014-2742-8
158.
TillettWJadonDShaddickG, et al.Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis. 2013;72(8):1358-1361. doi:10.1136/annrheumdis-2012-202608
159.
GallucciGTartaroneALeroseRLalingaAVCapobiancoAM. Cardiovascular risk of smoking and benefits of smoking cessation. J Thorac Dis. 2020;12(7):3866-3876. doi:10.21037/jtd.2020.02.47. https://search.proquest.com/docview/2434755674
160.
Ibáñez-BoschRRestrepo-VelezJMedina-MaloneMGarrido-CourelLPaniagua-ZudaireILoza-CortinaE. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients: A study based on carotid ultrasound. Rheumatol Int. 2017;37(1):107-112. doi:10.1007/s00296-016-3617-x. https://link.springer.com/article/10.1007/s00296-016-3617-x
161.
SzentpeteryAHealyGMBradyD, et al.Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity. Arthritis Rheumatol. 2018;70(3):396-407. doi:10.1002/art.40389
162.
ShenJWongKChengIT, et al.Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease. Ann Rheum Dis. 2017;76(7):1237-1244. doi:10.1136/annrheumdis-2016-210390
163.
AfifiLDaneshMJLeeKM, et al.Dietary behaviors in psoriasis: Patient-reported outcomes from a U.S. national survey. Dermatology and Therapy. 2017;7(2):227-242. doi:10.1007/s13555-017-0183-4
164.
TeyHLEeHLTanASThengTSWongSNKhooSW. Risk factors associated with having psoriatic arthritis in patients with cutaneous psoriasis. J Dermatol. 2010;37(5):426-430. doi:10.1111/j.1346-8138.2009.00745.x. https://api.istex.fr/ark:/67375/WNG-48SGBR4P-2/fulltext.pdf
165.
WuSChoELiWHanJQureshiAA. Alcohol intake and risk of incident psoriatic arthritis in women. J Rheumatol. 2015;42(5):835-840. doi:10.3899/jrheum.140808. https://www.ncbi.nlm.nih.gov/pubmed/25834201
166.
TurkMMurrayKAlammariY, et al.The effects of alcohol consumption and its associations with disease activity among 979 patients with inflammatory arthritis. RMD Open. 2021;7(2):e001510. doi:10.1136/rmdopen-2020-001510
167.
OrtolanALorenzinMTadiottoG, et al.Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients. Clin Rheumatol. 2019;38(10):2843-2850. doi:10.1007/s10067-019-04646-7. https://link.springer.com/article/10.1007/s10067-019-04646-7
168.
MinzerSLosnoRACasasR. The effect of alcohol on cardiovascular risk factors: Is there new information?Nutrients. 2020;12(4):912. doi:10.3390/nu12040912
DuvetorpAØstergaardMSkovL, et al.Quality of life and contact with healthcare systems among patients with psoriasis and psoriatic arthritis: Results from the NORdic PAtient survey of psoriasis and psoriatic arthritis (NORPAPP). Arch Dermatol Res. 2019;311(5):351-360. doi:10.1007/s00403-019-01906-z. https://link.springer.com/article/10.1007/s00403-019-01906-z
171.
KerschbaumerABakerDSmolenJSAletahaD. The effects of structural damage on functional disability in psoriatic arthritis. Ann Rheum Dis. 2017;76(12):2038-2045. doi:10.1136/annrheumdis-2017-211433
172.
WuJJPenfoldRBPrimatestaP, et al.The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis. J Eur Acad Dermatol Venereol. 2017;31(7):1168-1175. doi:10.1111/jdv.14175. https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.14175
